Sector News

Big new launches rocket cancer drug spending to $100B: IMS report

May 6, 2015
Life sciences
Cancer drug pricing is turning more and more heads, especially as critical payers threaten a crackdown in the oncology field. And there’s a reason for all the hullaballoo: Spending on oncology meds is increasing rapidly, new IMS numbers show.
 
According to the institute’s 2015 oncology trend report, global spending on cancer therapies shot up 10.3% in 2014 to reach $100 billion–up from $75 billion just 5 years earlier. In the U.S., per capita spending checked in at $99 last year, a big increase over the $71 it hit in 2010.
 
The reasons? In major developed markets, protected brands and big new launches have primarily driven the growth, the report says. Targeted therapies are doing their fair share to keep spending up, too, rising at a compound average growth rate of 14.6% over the past 5 years and now accounting for almost half the total worldwide tally.
 
And it doesn’t look like those spending numbers will be heading south anytime soon, either. IMS forecasts increased spending levels through 2018 that’ll expand at a compound average growth rate of 6% to 8%, bringing oncology spending to between $117 billion and $147 billion by that year. That’s even taking into account some market-share grab from cheaper biosimilars, IMS says, whose effects will be offset by climbing cancer diagnoses and treatment rates.
 
But payers, who have been making noise since pricey, next-gen Sovaldi from Gilead arrived to shake up the hep C scene, aren’t going to take the spending hikes lying down. Vocal critic and Express Scripts CMO Steve Miller has said he’s prepping an attack on cancer drug prices that’ll be a “much bigger effort” than the quick-hit tactics he used to ignite a price war and drive down hep C costs.
 
What does that mean for pharma? The changes won’t all come at once, and it’ll be a series of smaller moves instead of one leveling blow. They could include switching up the order in which costly drugs are used, or relying on a single expensive drug instead of a combo that offers marginal benefits.
 
Exactly what’s to come remains to be seen. But one thing’s for sure: It’s coming soon. “We want to be able to start influencing the market by 2016,” Miller told investors last week. “We are accumulating all the keys to the puzzle to be able to do this.”
 
By Carly Helfand 
 
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.